Amphastar Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Amphastar Pharmaceuticals Inc Unternehmen

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Amphastar Pharmaceuticals Inc Informationen



BörsenkürzelAMPH

Name des UnternehmensAmphastar Pharmaceuticals Inc

IPO-datumJun 25, 2014

CEOZhang (Yongfeng Yongfeng)

Anzahl der mitarbeiter2028

WertpapierartOrdinary Share

GeschäftsjahresendeJun 25

Addresse11570 6th St

StadtRANCHO CUCAMONGA

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl91730

Telefon19099809484

Websitehttps://amphastar.com/

BörsenkürzelAMPH

IPO-datumJun 25, 2014

CEOZhang (Yongfeng Yongfeng)

Führungskräfte von Amphastar Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Rong Zhou

Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.

208.23K

+5.34%

Dr. Howard S. Lee, Ph.D.

Independent Director

146.85K

-1.39%

Mr. William J. Peters

Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director

73.11K

+24.17%

Mr. Floyd F. Petersen

Independent Director

66.25K

-3.09%

Mr. Richard K. Prins

Lead Independent Director

30.06K

-6.81%

Ms. Gayle Deflin

Independent Director

5.79K

-35.32%

Dr. Yongfeng (Jack) Zhang, Ph.D.

President, Chief Executive Officer, Chief Scientific Officer, Director

--

Dr. Ziping (Mary) Luo, Ph.D.

Chairman of the Board, Chief Operating Officer, Chief Scientist

--

Ms. Diane G. Gerst

Independent Director

--

Dr. Michael A. Zasloff, M.D., Ph.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Rong Zhou

Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.

208.23K

+5.34%

Dr. Howard S. Lee, Ph.D.

Independent Director

146.85K

-1.39%

Mr. William J. Peters

Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director

73.11K

+24.17%

Mr. Floyd F. Petersen

Independent Director

66.25K

-3.09%

Mr. Richard K. Prins

Lead Independent Director

30.06K

-6.81%

Ms. Gayle Deflin

Independent Director

5.79K

-35.32%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Other products

229.65M

31.90%

BAQSIMI

185.36M

25.75%

Primatene Mist

108.67M

15.10%

Epinephrine

70.64M

9.81%

Glucagon

69.08M

9.60%

Andere

56.48M

7.85%

Nach RegionUSD

Name

Umsatz

Anteil

United States

681.42M

94.66%

France

35.28M

4.90%

China

3.18M

0.44%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Other products

229.65M

31.90%

BAQSIMI

185.36M

25.75%

Primatene Mist

108.67M

15.10%

Epinephrine

70.64M

9.81%

Glucagon

69.08M

9.60%

Andere

56.48M

7.85%

Aktionärsstatistik

Aktualisiert: Thu, May 14

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Applied Physics & Chemistry Laboratories, Inc.

15.48%

BlackRock Institutional Trust Company, N.A.

11.21%

Zhang (Jack Yongfeng)

7.44%

Luo (Mary Z)

5.25%

Dimensional Fund Advisors, L.P.

4.60%

Andere

56.02%

Aktionäre

Anteil

Applied Physics & Chemistry Laboratories, Inc.

15.48%

BlackRock Institutional Trust Company, N.A.

11.21%

Zhang (Jack Yongfeng)

7.44%

Luo (Mary Z)

5.25%

Dimensional Fund Advisors, L.P.

4.60%

Andere

56.02%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

43.87%

Investment Advisor/Hedge Fund

26.15%

Corporation

15.48%

Individual Investor

14.15%

Hedge Fund

5.05%

Research Firm

3.01%

Pension Fund

1.19%

Bank and Trust

0.44%

Family Office

0.28%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

582

35.15M

79.72%

-4.41M

2025Q4

586

33.97M

85.20%

+16.67K

2025Q3

603

33.96M

84.80%

+202.84K

2025Q2

607

33.74M

83.87%

-544.61K

2025Q1

597

34.53M

80.40%

-3.80M

2024Q4

593

35.69M

79.40%

-112.11K

2024Q3

575

35.68M

75.48%

+965.70K

2024Q2

565

34.64M

73.86%

+833.26K

2024Q1

548

33.97M

73.49%

-1.92M

2023Q4

531

33.91M

72.12%

+1.03M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Applied Physics & Chemistry Laboratories, Inc.

6.83M

15.05%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.94M

10.9%

+5.03K

+0.10%

Dec 31, 2025

Zhang (Jack Yongfeng)

2.77M

6.1%

+142.39K

+5.43%

Mar 15, 2026

Luo (Mary Z)

1.09M

2.4%

+69.40K

+6.79%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.80M

3.97%

+44.02K

+2.51%

Dec 31, 2025

TD Asset Management Inc.

1.96M

4.33%

+31.16K

+1.61%

Dec 31, 2025

State Street Investment Management (US)

1.53M

3.38%

+31.04K

+2.07%

Dec 31, 2025

Fuller & Thaler Asset Management Inc.

1.39M

3.07%

+40.54K

+2.99%

Dec 31, 2025

Marshall Wace LLP

1.24M

2.73%

+363.22K

+41.55%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Invesco Pharmaceuticals ETF

2.25%

State Street SPDR S&P Pharmaceuticals ETF

1.47%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.38%

Invesco S&P SmallCap 600 GARP ETF

1.12%

Acquirers Small and Micro Deep Value ETF

0.87%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.77%

Invesco S&P SmallCap Health Care ETF

0.56%

First Trust Small Cap Value AlphaDEX Fund

0.5%

Distillate Small/Mid Cash Flow ETF

0.45%

VictoryShares Small Cap Free Cash Flow ETF

0.37%

Invesco Pharmaceuticals ETF

Anteil2.25%

State Street SPDR S&P Pharmaceuticals ETF

Anteil1.47%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil1.38%

Invesco S&P SmallCap 600 GARP ETF

Anteil1.12%

Acquirers Small and Micro Deep Value ETF

Anteil0.87%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Anteil0.77%

Invesco S&P SmallCap Health Care ETF

Anteil0.56%

First Trust Small Cap Value AlphaDEX Fund

Anteil0.5%

Distillate Small/Mid Cash Flow ETF

Anteil0.45%

VictoryShares Small Cap Free Cash Flow ETF

Anteil0.37%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten